The impact of COVID-19 infection in pediatric and adult patients with primary immunodeficiency: a single center analysis
Abstract
Background: The global impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been profound, with over 760 million confirmed infections and almost 7 million deaths from coronavirus disease 2019 (COVID-19). The pandemic, officially declared in March 2020, has caused significant and irreversible changes in society. COVID-19 continues to pose a serious threat, ranging from asymptomatic cases to severe outcomes such as acute respiratory distress syndrome and organ failure, putting immense pressure on healthcare systems worldwide. The effects of SARS-CoV-2 infection on individuals with primary immunodeficiency (PID) are not yet fully understood. To date, the available research remains scarce, and the results do not yet provide conclusive evidence of a definitive link between PID and severe SARS-CoV-2 infection. In this study we present the clinical course and outcome of COVID-19 in individuals with PID.
Methods: This study is a retrospective analysis involving 65 patients, comprising both pediatric and adult individuals diagnosed with PID, who exhibited symptoms of SARS-CoV-2 infection and tested positive at The Hospital for Sick Children in Toronto, Ontario, Canada. The data was collected from October 2020 to December 2022.
Results: Sixty-five patients (36 children and 29 adults) were enrolled in our study. Our patients were diagnosed with primary immunodeficiency, and categorized as combined immunodeficiency, antibody deficiency, immune dysregulation disorder, phagocyte defect, intrinsic and innate immunity, or autoinflammatory disorder. Each of our patients had their COVID-19 infection confirmed through serology, rapid antigen test, and/or PCR. Among the study participants, 24 individuals had pre-existing lung conditions. At the time of contracting the infection, 42 patients had been vaccinated against SARS-CoV-2. The majority of patients in the study experienced mild to moderate symptoms of COVID-19.
Conclusion: Our patients with PID exhibited mild to moderate symptoms of COVID-19, and all made a full recovery without any complications.
Statement of Novelty: This study sheds light on impact of COVID-19 in individuals with primary immunodeficiency, revealing a noteworthy observation that patients exhibited mild to moderate symptoms, and remarkably, all experienced a complete recovery devoid of complications.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
Al-Musa A., LaBere B., Habiballah S., Nguyen A.A., and Chou J. 2022. Advances in clinical outcomes: what we have learned during the COVID-19 pandemic. J. Allergy Clin. Immunol. 149(2): 569–578.
Delavari S., Abolhassani H., Abolnezhadian F., Babaha F., Iranparast S., Ahanchian H., Moazzen N., Nabavi M., Arshi S., Fallahpour M., Bemanian M.H., Shokri S., Momen T., Sadeghi-Shabestari M., Molatefi R., Shirkani A., Vosughimotlagh A., Safarirad M., Sharifzadeh M., Pashangzadeh S., Salami F., Shirmast P., Rezaei A., Shad T.M., Mohraz M., Rezaei N., Hammarström L., Yazdani R., and Aghamohamamdi A. 2021. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J. Clin. Immunol. 41(2): 345–355.
Esenboga S., Ocak M., Akarsu A., Bildik H.N., Cagdas D., Iskit A.T., and Tezcan I. 2021. COVID-19 in patients with primary immunodeficiency. J. Clin. Immunol. 41(7): 1515–1522.
Fan Y., Li X., Zhang L., Wan S., Zhang L., and Zhou F. 2022. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther, 7(1): 141.
Guisado Hernández P., Blanco Lobo P., Villaoslada I., De Felipe B., Lucena J.M., Martín Gutierrez G., Castro M.J., Gutiérrez Valencia A., Sánchez Codez M.I., Gaboli M., Neth O., and Olbrich P. 2021. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J. Clin. Immun. 41(7): 1502–1506.
Jalil M., Pietras J., Ahmed S.N., Daniels P., and Hostoffer R. 2022. COVID-19 infection in patients with humoral immunodeficiency: a case series and literature review. Allergy Rhinol (Providence), 13: 215265752210960.
Marcus N., Frizinsky S., Hagin D., Ovadia A., Hanna S., Farkash M., Maoz-Segal R., Agmon-Levin N., Broides A., Nahum A., Rosenberg E., Kuperman A.A., Dinur-Schejter Y., Berkun Y., Toker O., Goldberg S., Confino-Cohen R., Scheuerman O., Badarneh B., Epstein-Rigbi N., Etzioni A., Dalal I., and Somech R. 2021. Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel. Front Immunol, 11: 614086.
Meyts I.Bucciol G.Quinti I.Neven B.Fischer A.Seoane E.Lopez-Granados E.Gianelli C.Robles-Marhuenda A.Jeandel P.-Y.Paillard C.Sankaran V.G.Demirdag Y.Y.Lougaris V.Aiuti A.Plebani A.Milito C.Dalm V.A.Guevara-Hoyer K.Sánchez-Ramón S.Bezrodnik L.Barzaghi F.Gonzalez-Granado L.I.Hayman G.R., Uzel G.Mendonça L.O.Agostini C.Spadaro G.Badolato R.Soresina A.Vermeulen F.Bosteels C.Lambrecht B.N.Keller M.Mustillo P.J.Abraham R.S.Gupta S.Ozen A.Karakoc-Aydiner E.Baris S.Freeman A.F.Yamazaki-Nakashimada M.Scheffler-Mendoza S.Espinosa-Padilla S.Gennery A.R.Jolles S.Espinosa Y.Poli M.C.Fieschi C.Hauck F.Cunningham-Rundles C.Mahlaoui N.IUIS Committee of Inborn Errors of Immunity,Warnatz K., Sullivan K.E., and Tangye S.G. (2021). Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J. Allergy Clin. Immunol. 147(2): 520–531.
Shields A.M., Burns S.O., Savic S., Richter A.G., Anantharachagan A., Arumugakani G., Baker K., Bahal S., Bermingham W., Bhole M., Boules E., Bright P., Burns S., Cleave B., Dempster J., Devlin L., Dhalla F., Drewe E., Duncan C., and Verma N. (2021). COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J. Allergy Clin. Immunol. 147(3): 870–875.e1.
Shields A.M., Tadros S., Al-Hakim A., Nell J.M., Lin M.M.N., Chan M., Goddard S., Dempster J., Dziadzio M., Patel S.Y., Elkalifa S., Huissoon A., Duncan C.J.A., Herwadkar A., Khan S., Bethune C., Elcombe S., Thaventhiran J., Klenerman P., Lowe D.M., Savic S., Burns S.O., and Richter A.G. (2022). Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. Front Immunol, 13: 984376.
Volk A., Covini-Souris C., Kuehnel D., De Mey C., Römisch J., and Schmidt T. (2022). SARS-CoV-2 neutralization in convalescent plasma and commercial lots of plasma-derived immunoglobulin. BioDrugs, 36(1): 41–53.
WHO Coronavirus (COVID-19) dashboard. [online]. Available from https://covid19.who.int. [accessed 30 July 2023]
Information & Authors
Information
Published In
LymphoSign Journal
Volume 10 • Number 4 • December 2023
Pages: 71 - 76
History
Received: 1 November 2023
Accepted: 27 November 2023
Accepted manuscript online: 1 December 2023
Version of record online: 11 January 2024
Copyright
© 2023.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
AzharAl Shaqaq, MarinaSham, LauraAbrego Fuentes, JennyGarkaby, JessicaWillett Pachul, LindaVong, JuliaUpton, VyKim, and Chaim M.Roifman. 2023. The impact of COVID-19 infection in pediatric and adult patients with primary immunodeficiency: a single center analysis. LymphoSign Journal.
10(4): 71-76. https://doi.org/10.14785/lymphosign-2023-0012
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
Cited by
1. Impact of the COVID-19 pandemic on patients with primary immunodeficiency
View Options
Login options
Check if you access through your login credentials or your institution to get full access on this article.
